News and Press Releases 2010

RSS Feeds

• December 21, 2010
  Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
• November 29, 2010
  AFFYMAX AND TAKEDA CONFIRM U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, FOLLOWING MEETING WITH FDA
• September 23, 2010
  Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
• September 2, 2010
  Orexigen® Therapeutics and Takeda Enter into Partnership to Commercialize Contrave® in North America
• August 5, 2010
  AFFYMAX AND TAKEDA ANNOUNCE PRELIMINARY U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE
• July 14, 2010
  Takeda Responds to FDA Advisory Committee Recommendation
• June 21, 2010
  ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
• June 21, 2010
  New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
• June 21, 2010
  AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE WITH SOME DIFFERENCES NOTED IN SECONDARY ANALYSES
• May 3, 2010
  Pivotal Phase 3 Data Demonstrated Investigational Compound Azilsartan Medoxomil Lowered Blood Pressure in Head-to-Head Comparator Trials
• April 28, 2010
  Takeda Provides Update on Patent Litigation for ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the U.S.
• April 27, 2010
  Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension
• April 26, 2010
  Proton Pump Inhibitor DEXILANT™ (dexlansoprazole) Now Available in U.S. Pharmacies
• March 4, 2010
  KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion
• February 22, 2010
  Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
• February 9, 2010
  Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix® (clopidogrel bisulfate)